抗凝护理专科门诊在规范肺栓塞患者治疗中的临床实践被引量：15

Clinical practice of nurse-led anticoagulant clinics in standard treatment of patients with pulmonary embolism

下载PDF

导出

摘要肺栓塞患者规范化的抗凝治疗是一项复杂、系统、细致的工作,关乎到患者疾病的转归,开设抗凝护理专科门诊可为患者提供规范化的用药管理。我院于2016年3月建立医护协作型抗凝护理专科门诊,以护士为主导规范抗凝管理,取得了良好成效,提高了抗凝治疗患者的依从性及国际标准化比值达标率,减少了出血事件的发生。本文介绍抗凝护理专科门诊的建立与实施,为护士规范肺栓塞患者的抗凝管理提供借鉴。 Standard anticoagulation treatment of pulmonary embolism,which is closely related with the outcomes of patients,is a complex,systematic and meticulous work.The establishment of a nurse-led anticoagulant clinic can provide criteria of anticoagulant treatment for patients.Ever since the set up of the anticoagulant clinic led by specialist nurses in March 2016,pretty good results have been achieved including improved patients'compliance,better international normalized ratio level and reduced rate of bleeding events.This article introduces the establishment and implementation of the nurse-led anticoagulant clinic to share our experience of standard anticoagulant treatment for patients with pulmonary embolism.

作者崔英黄金文唐小红向梅龚娟妮杨媛华 CUI Ying;HUANG Jinwen;TANG Xiaohong;XIANG Mei;GONG Juanni;YANG Yuanhua(Department of Respiratory and Critical Care Medicine,Beijing Chao-Yang Hospital,Capital Medical University,Beijing,100020,China)

机构地区首都医科大学附属北京朝阳医院呼吸与危重症医学科

出处《中国护理管理》 CSCD 北大核心 2020年第10期1458-1461,共4页 Chinese Nursing Management

基金国家重点研发计划精准医学研究重点专项2016年度项目(2016YFC0905600)。

关键词抗凝护理抗凝护理专科门诊肺栓塞华法林专科护理门诊 anticoagulation care clinic led by specialist nurses for anticoagulation pulmonary embolism warfarin nurse-led clinics

分类号 R473.5 [医药卫生—护理学]

引文网络
相关文献

参考文献2

1赵飞燕,崔英,肖树芹.肺血栓栓塞症患者华法林抗凝治疗的知识、态度及行为的调查分析[J].中华护理杂志,2016,51(12):1451-1455. 被引量：26
2张喆,罗梦林,田敏,张艺,刘全义.华法林抗凝患者的抗凝现状调查及分析[J].中国医院药学杂志,2014,34(2):127-130. 被引量：46

二级参考文献22

1张彦丽,王景红,顾媛媛,桂班月.华法林与中草药的相互作用[J].中国药物警戒,2011,8(1):41-45. 被引量：31
2Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient char- acteristics upon warfarin dose requirements: proposal for a new dosing regimen[J]. Blood,2005,106, 2329-2333.
3Biss TT, Kamali F. Warfarin anticoagulation in children: is there a role for a personalized approach to dosing? [J]. Phar- macogenomics, 2012,13( 11 ), 1211-1214.
4Streif W,Andrew M,Marzinotto V,etal. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients[J]. Blood, 1999,94 (9) :3007-3014.
5McDonald MG, Au NT, Wittkowsky AK, et al. Warfarin- amiodarone drug-drug interactions: determination of[I] (u)/K (I,u) for amiodarone and its plasma metabolites[J]. Clin Pharmacol Ther,2012,91 (4) :709-717.
6Chan TY. Interaction between warfarin and danshen (Salvia miltiorrhiza) [J]. Ann Pharmacother, 2001 , 35 (4) : 501-504.
7Zhou X, Chan K, Yeung JH. Herb-drug interactions with Danshen (Salvia miltiorrhiza): a review on the role of cyto- chrome P450 enzymes[J]. Drug MetaboI Drug Interact,2012, 27(1 ) :9-18.
8Yuan C S, Wei G, Dey L, etal. Brief communication: Ameri- can ginseng reduces warfarin's effeet in healthy patients: a ran- domized, controlled Trial[J]. Ann Intern Med, 2004, 141 ( 1 ) : 23-27.
9Ageno W,Gallus AS, Wittkowsky A. Oral anticoagulant ther- apy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest,2012,141:e44S-e88S.
10Oldenburg J, Quenzel EM, Harbrecht U,et al. Missense mu- tations at ALA-10 in the factor IX propeptide= an insignificant variant in normal life but a decisive cause of bleeding during o- ral anticoagulant therapy[J]. Br J Haematol, 1997,98 ( 1 ) : 240- 244.